Chamber
Meeting of the Parliament 20 February 2013
20 Feb 2013 · S4 · Meeting of the Parliament
Item of business
New Medicines
I welcome the opportunity to debate a very serious and sensitive issue, particularly as a member of the Health and Sport Committee, as the issue forms part of our current work plan.
I welcome the Scottish Government’s £21 million rare conditions medicines fund, which is a response to the interim recommendations from Professor Charles Swainson, who is leading the review of the individual patient treatment request system. I hope that that review, along with the work that Professor Philip Routledge and Professor Bill Scott are doing on the new medicines approval process of the SMC and the implementation of SMC advice by health boards, will help to improve access to medicines in Scotland and ensure that the system is as flexible and responsive as it can and should be. The review is on-going, of course, and we await the final report to the Government in the spring. I note the cabinet secretary’s undertaking to take forward the recommendations. The Government therefore is listening and has listened to the concerns that have been raised by some of our clinicians and patients on access to new medicines.
As the Conservative Party’s motion also refers to the need
“to promote Scotland as a centre for medical innovation and research”,
I want to reflect on the Scottish Government’s efforts in that area. If we consider, for example, its statement of intent for innovation in health, which was launched last June, we will see that it is clear that it is promoting innovation and excellence through the NHS, including new medicines, and that that is very much linked to biosciences and the employment and sustainable growth that we all hope that that sector will continue to generate.
There are projects such as the Edinburgh BioQuarter and the partnership between BioCity Scotland at Newhouse in Lanarkshire and the University of Dundee, which has attracted the biggest-ever investment of its kind in Scotland. European investment of £100 million for a drug discovery project suggests to me that Scotland’s life sciences sector, supported as it is by our world-class universities and their research capability, has every opportunity to grow and flourish.
I also want to touch on the issue of the cancer drugs fund. I recognise of course that it is a very sensitive matter and one that confronts policy makers and the medical profession in all publicly funded health systems. The difficulty in accepting the principle of a special fund for cancer drugs is that we as policy makers implicitly assert that cancer is somehow more significant than other serious long-term or life-threatening conditions. I do not believe that that is our task or that by so doing we would serve the wider interests of all those who rely on our national health service.
I welcome the Scottish Government’s £21 million rare conditions medicines fund, which is a response to the interim recommendations from Professor Charles Swainson, who is leading the review of the individual patient treatment request system. I hope that that review, along with the work that Professor Philip Routledge and Professor Bill Scott are doing on the new medicines approval process of the SMC and the implementation of SMC advice by health boards, will help to improve access to medicines in Scotland and ensure that the system is as flexible and responsive as it can and should be. The review is on-going, of course, and we await the final report to the Government in the spring. I note the cabinet secretary’s undertaking to take forward the recommendations. The Government therefore is listening and has listened to the concerns that have been raised by some of our clinicians and patients on access to new medicines.
As the Conservative Party’s motion also refers to the need
“to promote Scotland as a centre for medical innovation and research”,
I want to reflect on the Scottish Government’s efforts in that area. If we consider, for example, its statement of intent for innovation in health, which was launched last June, we will see that it is clear that it is promoting innovation and excellence through the NHS, including new medicines, and that that is very much linked to biosciences and the employment and sustainable growth that we all hope that that sector will continue to generate.
There are projects such as the Edinburgh BioQuarter and the partnership between BioCity Scotland at Newhouse in Lanarkshire and the University of Dundee, which has attracted the biggest-ever investment of its kind in Scotland. European investment of £100 million for a drug discovery project suggests to me that Scotland’s life sciences sector, supported as it is by our world-class universities and their research capability, has every opportunity to grow and flourish.
I also want to touch on the issue of the cancer drugs fund. I recognise of course that it is a very sensitive matter and one that confronts policy makers and the medical profession in all publicly funded health systems. The difficulty in accepting the principle of a special fund for cancer drugs is that we as policy makers implicitly assert that cancer is somehow more significant than other serious long-term or life-threatening conditions. I do not believe that that is our task or that by so doing we would serve the wider interests of all those who rely on our national health service.
In the same item of business
The Deputy Presiding Officer (John Scott)
Con
The next item of business is a debate on motion S4M-05664, in the name of Jackson Carlaw, on health. 15:55
Jackson Carlaw (West Scotland) (Con)
Con
The Conservatives have framed the motion with a view to making qualitative progress on the subject of cancer in this afternoon’s debate. In that spirit, we w...
Mark McDonald (North East Scotland) (SNP)
SNP
Will the member take an intervention?
Jackson Carlaw
Con
I will in due course.It is not a choice between detection and making drugs available—those are two halves of the approach that the Parliament should ensure i...
Mark McDonald
SNP
I know that Mr Carlaw was making a fleeting political point, but I will quote to him what Breakthrough Cancer Scotland said:“Breakthrough would suggest that ...
Jackson Carlaw
Con
The member has made his point. Many of the quotes used by Mark McDonald are from papers that were issued at the commencement of the cancer drugs fund in the ...
Joan McAlpine (South Scotland) (SNP)
SNP
Will the member take an intervention?
Jackson Carlaw
Con
No—I want to make the point.I am not someone who gets overly emotional in politics—I have been around long enough to know that the hard knocks come and they ...
The Cabinet Secretary for Health and Wellbeing (Alex Neil)
SNP
This is a difficult and very sensitive subject. I think that we all recognise that making decisions about which medicines to provide for national health serv...
Jim Eadie (Edinburgh Southern) (SNP)
SNP
Does the cabinet secretary recognise that public trust and confidence go to the heart of the debate, and that the public have a right to expect that if their...
Alex Neil
SNP
I will deal with some of those points later in my speech.Thousands of medicines in various doses and formulations are available to clinicians in the UK. In S...
Jackie Baillie (Dumbarton) (Lab)
Lab
I welcome the opportunity to debate access to new medicines in the NHS and the tone of the speeches made by Jackson Carlaw and the cabinet secretary. I also ...
The Deputy Presiding Officer (Elaine Smith)
Lab
You are in your last minute.
Jackie Baillie
Lab
Fourteen different ways of doing things is no longer acceptable.Let me turn to the orphan drugs fund. That is very welcome, but it must not just be a stickin...
The Deputy Presiding Officer
Lab
The debate is extremely tight, and we have already lost a member from it. I ask members to take only their four minutes.16:18
Aileen McLeod (South Scotland) (SNP)
SNP
I welcome the opportunity to debate a very serious and sensitive issue, particularly as a member of the Health and Sport Committee, as the issue forms part o...
Jackson Carlaw
Con
I understand the point that the member is making, but she has just referred to the £21 million that has been made available for the rare conditions medicine ...
Aileen McLeod
SNP
I speak as somebody who has worn both hats: one as a policy maker and one as a cancer victim and survivor. I am therefore acutely aware of how cancer suffere...
Duncan McNeil (Greenock and Inverclyde) (Lab)
Lab
I am sure that we will hear a lot in the debate about the National Institute for Health and Clinical Excellence, the Scottish Medicines Consortium, individua...
Joan McAlpine
SNP
I think that the member was referring to my article in the Daily Record and I thank him for taking an intervention from me, which Mr Carlaw did not have the ...
The Deputy Presiding Officer
Lab
Please be brief.
Joan McAlpine
SNP
Does the member agree that there is an issue to do with pharmaceutical companies holding the health service to ransom—
Duncan McNeil
Lab
The member will speak in the debate. I hope that I will be given additional time.
The Deputy Presiding Officer
Lab
I am afraid that this is a very short debate.
Duncan McNeil
Lab
I accept that the premise of Ms McAlpine’s article was that politicians should not be involved in the process at all. However, we set the parameters and we p...
The Deputy Presiding Officer
Lab
You must conclude, Mr McNeil.
Duncan McNeil
Lab
That is why the cabinet secretary instigated a review of the process. It matters that we lost precious time. That time was not as precious for us as it was f...
The Deputy Presiding Officer
Lab
I advise members that we might have to lose another speaker from the debate. Members must take interventions in their own time.16:26
Bob Doris (Glasgow) (SNP)
SNP
I welcome the debate, although I cannot accept the Conservative motion. I will explain to Jackson Carlaw why that is the case. Mr Carlaw will not share this ...
Dr Richard Simpson (Mid Scotland and Fife) (Lab)
Lab
That is the clinician’s decision.